

Ayuda TRANSCAN 3 – JTC 2024

Adjudicaciones

Dra. Julie Earl

Instituto Ramón y Cajal de
Investigación Sanitaria (IRYCIS)

ACCELERATE: FunctionAl preCision
mediCinE pLatform for the trEatment of
pancReATic cancEr

Dr. Antonio Calles

Instituto de Investigación Sanitaria
Gregorio Marañón (IISGM)

DOPPLER-LC: Development Of Patient-
derived organoid PLatforms for Evading
Resistances in Lung
Cancer

Dra. Irene Ferrer

Instituto de investigación Hospital
12 de octubre (i+12)

Dra. Rebeca Sanz-Pamplona

Instituto de Investigación Sanitaria
Aragón (IIS Aragón)

ioAVATAR: Immune oncology Drug
Discovery & Decision - Advanced ex
Vivo Approach To Accelerate
Response prediction for combined
therapies in ovarian cancer

Dra. Judith Guash

Instituto de Ciencia de Materiales
de Barcelona (ICMAB-CSIC)

LUNGoids: Subtype-specific Lung Cancer
Organoids based on artificial ECM for
Precision Oncology: Closing the Gap
Between Preclinical Models and Patient Care

Dra. Paula Espinosa

Consorcio Hospital General
Universitario de Valencia

Dr. José Luis Pérez García
Instituto de Investigación Sanitaria
de Navarra (IdiSNA)

METRICs: Metabolism/Metagenomics-based
strategies for sensitization to Radio- and
Immuno- therapy Combinations

Dr. Mariano Ponz
Instituto de Investigación Sanitaria
de Navarra (IdiSNA)

PREDICT-BC: Patient-derived models
for the Research and Evaluation of
Discovery and Innovation in
Combination Therapies for Biliary tract
Cancer

Dr. Tian Tian
Vall d'Hebron Instituto de
Oncología (VHIO)

Dr. Arantxa Tabernero
Universidad de Salamanca (USAL)

SeqPerGlio: Intraoperative tumour
sequencing for personalized loco-
regional drug combination therapy
against glioblastoma recurrences

Dr. María Martínez-García
Hospital del Mar Research Institute

Dr. Jesús María Bañales
Instituto de Investigación Sanitaria
Biogipuzkoa (IIS Biogipuzkoa)

TITAN: Novel Cancer Therapy:
Inducing Double-strand DNA Breaks
to Foster Tumour Cell Death,
Antigenicity and Immunotherapy
Response in New Personalized Models

Dr. Fernando Pedro Cossío
Universidad del País Vasco
(UPV/EHU)

Dr. Felipe Prosper
Instituto de Investigación Sanitaria
de Navarra (IdiSNA)

TOSCANINI: TAD disruption and
aberrant expression as leukemia
metabolic vulnerabilities for
novel combination therapy tests in a
drug screening platform

Dra. Ana Espinosa de los Monteros
Instituto de Ciencia de Materiales
de Madrid (ICMM-CSIC)

XPANTHER: Radiothermal-Driven Immune
Activation to Tackle Pancreatic Hypoxic
Tumors

Dr. José Manuel Udías Moinelo
Instituto de Investigación Sanitaria
Hospital Clínico San Carlos (IdiSSC)